Driver Response to Hydrogen Fuel Cell Buses in a Real-World Setting Study of a Northern California Transit Bus Fleet

被引:7
|
作者
Lipman, Timothy E. [1 ]
Gray-Stewart, Ananda L. [1 ]
Lidicker, Jeffrey [2 ]
机构
[1] Univ Calif Berkeley, Transportat Sustainabil Res Ctr, Berkeley, CA 94704 USA
[2] Michigan Technol Univ, Dept Civil & Environm Engn, Houghton, MI 49931 USA
关键词
Fuel economy;
D O I
10.3141/2502-06
中图分类号
TU [建筑科学];
学科分类号
0813 ;
摘要
This study examined bus drivers' acceptance of fuel cell electric buses in Alameda-Contra Costa Transit in the San Francisco Bay Area of California. Of the 145 surveys issued, 47 drivers completed a written survey, for a 32% response rate. The study focused on a key attribute for potential success of alternative urban bus technology: the driver acceptance factor. Technology performance flaws that are undesirable or annoying to the bus drivers may also be disruptive to passengers. Furthermore, because of using the buses throughout their full duty cycle, drivers are in a unique position to identify key opportunities to improve the new technology options as they emerge and evolve. The study found that drivers, in general, rated the hydrogen fuel cell buses to be at the same or better performance than diesel buses for handling, ride quality, acceleration, and braking. For quiet operation, the drivers rated the new buses as excellent. When asked how they liked the experimental hydrogen fuel cell buses, drivers responded at just above neutral, with the most common response being "the same" as diesel buses followed by "much better." Those drivers who said that they considered fuel economy when purchasing a vehicle liked the fuel cell buses more. Older drivers preferred the diesel buses, and male drivers preferred the new fuel cell buses. Perceptions of safety were mixed, with some drivers expressing safety concerns independent of how much training they had received.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 50 条
  • [41] Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
    Gristina, Valerio
    Barraco, Nadia
    La Mantia, Maria
    Castellana, Luisa
    Insalaco, Lavinia
    Bono, Marco
    Perez, Alessandro
    Sardo, Delia
    Inguglia, Sara
    Iacono, Federica
    Cutaia, Sofia
    Russo, Tancredi Didier Bazan
    Francini, Edoardo
    Incorvaia, Lorena
    Badalamenti, Giuseppe
    Russo, Antonio
    Galvano, Antonio
    Bazan, Viviana
    CANCERS, 2022, 14 (23)
  • [42] Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
    Macia-Rivas, Lola
    Fernandez-Laguna, Clara luz
    Alvarez-Asteinza, Cristina
    Maray, Ivan
    Carbajales-Alvarez, Monica
    Lozano-Blazquez, Ana
    ANTICANCER RESEARCH, 2023, 43 (04) : 1681 - 1688
  • [43] Real-world large-scale study of ERBB2 gene fusions and its response to afatinib in Chinese non-small cell lung cancer (NSCLC): A multicenter study.
    Xu, Chunwei
    Wang, Wen Xian
    Zhang, Quxia
    Chen, Yu
    Cai, Xiuyu
    Fang, Yong
    Zhu, You-cai
    Huang, Yun-Jian
    Wang, Hong
    Zhuang, Wu
    Zhang, Yinbin
    Wang, Liping
    Jiang, Xiaofang
    Cai, Shangli
    Huang, Jianhui
    Feng, Shuitu
    Fang, Meiyu
    Chen, Gang
    Lv, Tangfeng
    Song, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multicountry observational study.
    Jazieh, Abdul Rahman
    Onal, Huseyin Cem
    Tan, Daniel Shao-Weng
    Soo, Ross A.
    Prabhash, Kumar
    Kumar, Amit
    Huggenberger, Reto
    Robb, Stephen
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
    Eric Nadler
    Bhakti Arondekar
    Kathleen Marie Aguilar
    Jie Zhou
    Jane Chang
    Xinke Zhang
    Vivek Pawar
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 671 - 690
  • [46] Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study
    Nadler, Eric
    Arondekar, Bhakti
    Aguilar, Kathleen Marie
    Zhou, Jie
    Chang, Jane
    Zhang, Xinke
    Pawar, Vivek
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (03) : 671 - 690
  • [47] Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study
    Hotta, Masaaki
    Iwama, Ayako
    Hoshiyama, Tokiko
    Tsubokura, Yukie
    Yoshimura, Hideaki
    Kono, Yumiko
    Fujita, Shinya
    Satake, Atsushi
    Ito, Tomoki
    BLOOD, 2023, 142
  • [48] Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients
    Matsuki, Takashi
    Okamoto, Isaku
    Fushimi, Chihiro
    Takahashi, Hideaki
    Okada, Takuro
    Kondo, Takahito
    Sato, Hiroki
    Ito, Tatsuya
    Tokashiki, Kunihiko
    Tsukahara, Kiyoaki
    Hanyu, Kenji
    Masubuchi, Tatsuo
    Tada, Yuichiro
    Miura, Kouki
    Omura, Go
    Sawabe, Michi
    Kawakita, Daisuke
    Yamashita, Taku
    CANCERS, 2020, 12 (11) : 1 - 13
  • [49] Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
    Rattanathammethee, Thanawat
    Norasetthada, Lalita
    Bunworasate, Udomsak
    Wudhikarn, Kitsada
    Julamanee, Jakrawadee
    Noiperm, Panarat
    Lanamtieng, Theerin
    Phiphitaporn, Pisa
    Navinpipat, Manassamon
    Kanya, Piyapong
    Jit-ueakul, Dusit
    Wongkhantee, Somchai
    Suwannathen, Thanongsak
    Chaloemwong, Juthatip
    Wong, Peerapon
    Makruasi, Nisa
    Khuhapinant, Archrob
    Prayongratana, Kannadit
    Niparuck, Pimjai
    Kanitsap, Nonglak
    Suwanban, Tawatchai
    Intragumtornchai, Tanin
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1887 - 1895
  • [50] Correction: Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study
    Alvydas Cesas
    Vincas Urbonas
    Skaiste Tulyte
    Rasa Janciauskiene
    Sigita Liutkauskiene
    Ingrida Grabauskyte
    Ignas Gaidamavicius
    Journal of Cancer Research and Clinical Oncology, 151 (3)